A phase 3 trial of extended release oral dalfampridine in multiple sclerosis.

Abstract

OBJECTIVE A previous phase 3 study showed significant improvement in walking ability in multiple sclerosis (MS) patients treated with oral, extended-release dalfampridine (4-aminopyridine) 10mg twice daily. The current study was designed to confirm efficacy and further define safety and pharmacodynamics. METHODS This was a 39-center, double-blind trial in… (More)
DOI: 10.1002/ana.22240

Topics

Cite this paper

@article{Goodman2010AP3, title={A phase 3 trial of extended release oral dalfampridine in multiple sclerosis.}, author={Andrew D. Goodman and Theodore R. Brown and Keith Edwards and Lauren B. Krupp and Randall T. Schapiro and Ron Cohen and Lawrence N. Marinucci and Andrew R. Blight}, journal={Annals of neurology}, year={2010}, volume={68 4}, pages={494-502} }